VISEN PHARMA-B(02561),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

02561 VISEN PHARMA-B

Not Yet Opened 01-15 15:58:32

34.420

+0.140

+0.41%

High35.080	Low33.000	Vol31.00K
Open34.280	D1 Closing34.280	Amplitude6.07%
Mkt Cap3.92B	Tradable Cap3.92B	Total Shares114.00M
T/O1.04M	T/O Rate0.03%	Tradable Shares114.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"02561","market":"HK","secType":"STK","nameCN":"VISEN PHARMA-B","latestPrice":34.42,"timestamp":1768463912685,"preClose":34.28,"halted":0,"volume":31000,"delay":0,"floatShares":113999999,"shares":113999999,"eps":-1.946273,"marketStatus":"Not Yet Opened","change":0.14,"latestTime":"01-15 15:58:32","open":34.28,"high":35.08,"low":33,"amount":1042700,"amplitude":0.060677,"askPrice":34.8,"askSize":1500,"bidPrice":33,"bidSize":500,"shortable":3,"etf":0,"ttmEps":-2.087,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1768527000000},"marketStatusCode":0,"adr":0,"listingDate":1742486400000,"exchange":"SEHK","adjPreClose":34.28,"openAndCloseTimeList":[[1768440600000,1768449600000],[1768453200000,1768464000000]],"volumeRatio":1.02717,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02561","defaultTab":"news","newsList":[{"id":"1117026279","title":"VISEN Pharmaceuticals (02561) Publishes Monthly Return for November 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=1117026279","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1117026279?lang=en_us&edition=fundamental","pubTime":"2025-12-04 16:50","pubTimestamp":1764838216,"startTime":"0","endTime":"0","summary":"VISEN Pharmaceuticals (Stock Code: 02561) published its monthly return for the period ended 30 November 2025. The filing shows an authorized share capital of 500,000,000 ordinary shares at par value...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02561"],"gpt_icon":0},{"id":"1189074067","title":"HK Stock Movement | VISEN PHARMA-B (02561) Surges Over 12% Again as Lonapegsomatropin Nears Approval; Company Recently Enters Strategic Partnership with Tofflon","url":"https://stock-news.laohu8.com/highlight/detail?id=1189074067","media":"Stock News","labels":["corporation","productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189074067?lang=en_us&edition=fundamental","pubTime":"2025-12-02 11:10","pubTimestamp":1764645014,"startTime":"0","endTime":"0","summary":"VISEN PHARMA-B (02561) surged over 12% again, rising 7.11% to HKD 35.26 by the time of writing, with a turnover of HKD 1.9082 million. On the news front, Anke Biotechnology recently disclosed...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0251","300171","BK1161","02561"],"gpt_icon":0},{"id":"1194247422","title":"HK Stock Movement | VISEN PHARMA-B (02561) Surges Over 7% Intraday as Core Product Lonapegsomatropin Nears Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1194247422","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194247422?lang=en_us&edition=fundamental","pubTime":"2025-12-01 09:54","pubTimestamp":1764554054,"startTime":"0","endTime":"0","summary":"VISEN PHARMA-B (02561) rose more than 7% intraday, and as of press time, it was up 3.64% to HK$31.88. The catalyst behind the rally is recent progress disclosed by Anke Biotechnology regarding its...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02561"],"gpt_icon":0},{"id":"2586288667","title":"Here's Why We're Not At All Concerned With VISEN Pharmaceuticals' (HKG:2561) Cash Burn Situation","url":"https://stock-news.laohu8.com/highlight/detail?id=2586288667","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586288667?lang=en_us&edition=fundamental","pubTime":"2025-11-26 06:09","pubTimestamp":1764108548,"startTime":"0","endTime":"0","summary":"Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2561/visen-pharmaceuticals-shares/news/heres-why-were-not-at-all-concerned-with-visen-pharmaceutica","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2561/visen-pharmaceuticals-shares/news/heres-why-were-not-at-all-concerned-with-visen-pharmaceutica","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1161","02561"],"gpt_icon":0},{"id":"1117424956","title":"Riding the Hong Kong Stock Rally: Bull Market Dawns in the East 2026 – 10th Zhitong Finance Capital Markets Annual Conference Invites You to a Capital Feast","url":"https://stock-news.laohu8.com/highlight/detail?id=1117424956","media":"Stock News","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1117424956?lang=en_us&edition=fundamental","pubTime":"2025-11-18 08:56","pubTimestamp":1763427395,"startTime":"0","endTime":"0","summary":"As the fourth technological revolution sweeps across the globe, with AI and large model technologies reaching critical breakthroughs, capital engines are driving the revaluation of Chinese assets at...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BVYPNQ40.USD","HK0000252152.HKD","02171","BK1144","01762","BK1516","BK1539","BK1518","BK1556","BK1586","02453","BK1531","00302","00382","06069","00826","BK1596","BK1225","02105","02157","BK1193","09996","02380","BK1618","LU1497733631.SGD","SG9999014674.SGD","BK1155","09911","BK1209","BK1188","BK1137","BK1594","BK1194","02533","00003","06996","03315","02670","BK1583","IE00BYV24P56.USD","02420","BK1161","BK1229","02411","SG9999002950.SGD","06919","BK1124","HK0000500386.USD","BK1104","BK1147","IE00BGHQDM52.EUR","02551","HK0000252160.HKD","LU2488822045.USD","01228","BK1148","00552","00196","BK1606","02587","BK1578","LU2476274308.USD","BK1575","BK1228","02886","SG9999001069.SGD","09919","00290","BK1221","01333","BK1186","BK1095","02268","BK1542","BK1191","SG9999015986.USD","BK1114","BK1521","IE00BVYPNP33.GBP","01318","BK1175","BK1529","03145","01167","01773","06100","LU1634259391.SGD","LU0348766576.USD","01809","00867","06608","SG9999003461.SGD","06677","01969","BK1579","BK1110","LU1522347837.USD","BK1608","01783","BK1552","BK1150","09959","BK1141","BK1178","BK1207","BK1613","IE00BMCWC346.EUR","BK1582","IE00BPRC5H50.USD","LU1497733557.USD","00699","02561","BK1219","BK1183","BK1216","06660","BK1619","01164","02858","BK1230","BK1202","00855","02616","09678","06682","00604","06090","BK1140","SG9999015945.SGD","02627","BK1530","02142","BK1100","00861","BK1139","BK1524","02167","BK1585","BK1591","SG9999015978.USD","BK1171","02279","09860","BK1109","02256","02509","01681","BK1116","06633","BK1555","BK1527","00305","BK1593","BK1609","01651","BK1224","BK1500","LU0348767384.USD","LU2778985437.USD","09878","LU0348825331.USD","SG9999015952.SGD","BK1506","01907","BK1125","BK1577","LU0417516902.SGD","LU1497734951.SGD","02511","LU2476274720.SGD","BK1592","BK1258","03658","BK1574","LU1634259557.SGD","IE00B543WZ88.USD","LU1808992512.USD","BK1142","03738","LU2460026573.USD","BK1163","02567","BK1595","02177","06609","02431","BK1132","02096","BK1587","IE00B5MMRT66.SGD","02488","00363","BK1131","SG9999004220.SGD"],"gpt_icon":0},{"id":"1101244851","title":"VISEN PHARMA-B (02561) Rises Over 4% as Palopegteriparatide Completes First Prescription in Boao","url":"https://stock-news.laohu8.com/highlight/detail?id=1101244851","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1101244851?lang=en_us&edition=fundamental","pubTime":"2025-11-03 10:28","pubTimestamp":1762136899,"startTime":"0","endTime":"0","summary":"VISEN PHARMA-B (02561) surged over 4%, reaching HK$39.8 by the time of writing, marking a 4.68% increase. The uptick follows the recent first prescription of Palopegteriparatide (TransCon PTH) at...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02561"],"gpt_icon":0},{"id":"2575060164","title":"VISEN Pharmaceuticals Names CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2575060164","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575060164?lang=en_us&edition=fundamental","pubTime":"2025-10-13 20:35","pubTimestamp":1760358918,"startTime":"0","endTime":"0","summary":"VISEN Pharmaceuticals (HKG:2561) named Lu Ying as its CFO effective Monday, a same-day Hong Kong bourse filing said.Lu served as the CFO of VivaVision Biotech from August 2021 to October 2025.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","02561"],"gpt_icon":0},{"id":"1174517174","title":"VISEN PHARMA-B (02561): Lu Ying Appointed as Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=1174517174","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1174517174?lang=en_us&edition=fundamental","pubTime":"2025-10-13 17:58","pubTimestamp":1760349507,"startTime":"0","endTime":"0","summary":"VISEN PHARMA-B (02561) announced that Lu Ying has been appointed as the company's Chief Financial Officer, effective October 13, 2025.","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02561","BK1161"],"gpt_icon":0},{"id":"2575647419","title":"Visen Pharmaceuticals Appoints Lu Ying as New Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2575647419","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575647419?lang=en_us&edition=fundamental","pubTime":"2025-10-13 17:58","pubTimestamp":1760349498,"startTime":"0","endTime":"0","summary":"Visen Pharmaceuticals has announced the appointment of Mr. Lu Ying as Chief Financial Officer, effective October 13, 2025. Mr. Lu brings over 19 years of financial management experience, having previously served as CFO at VivaVision Biotech Limited and held financial leadership roles at Allergan and Bayer Healthcare. The board of directors' composition remains unchanged, with Mr. Lu An-Bang continuing as Executive Director and CEO.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Visen Pharmaceuticals published the original content used to generate this news brief on October 13, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251013:nNDL2ZfTkZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02561","BK1161"],"gpt_icon":0},{"id":"2575474955","title":"BRIEF-Visen Pharmaceuticals Appoints Lu Ying As CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2575474955","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575474955?lang=en_us&edition=fundamental","pubTime":"2025-10-13 17:54","pubTimestamp":1760349285,"startTime":"0","endTime":"0","summary":"BRIEF-Visen Pharmaceuticals Appoints Lu Ying As CFOOct 13 (Reuters) - Visen Pharmaceuticals 2561.HK:APPOINTS LU YING AS CFOFurther company coverage: 2561.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251013:nFWN3VT01G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02561","BK1161"],"gpt_icon":0},{"id":"2575747498","title":"Visen Pharmaceuticals - Appoints Lu Ying as CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2575747498","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575747498?lang=en_us&edition=fundamental","pubTime":"2025-10-13 17:54","pubTimestamp":1760349263,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251013:nFWN3VT01G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02561","BK1161"],"gpt_icon":0},{"id":"1188705635","title":"VISEN PHARMA-B Surges Over 3% in Morning Trading as Long-Acting Growth Hormone Awaits Approval This Year","url":"https://stock-news.laohu8.com/highlight/detail?id=1188705635","media":"Deep News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188705635?lang=en_us&edition=fundamental","pubTime":"2025-10-06 11:50","pubTimestamp":1759722636,"startTime":"0","endTime":"0","summary":"VISEN PHARMA-B (02561) saw its share price climb 3.08% during morning trading, reaching HK$44.80 with a turnover of HK$1.042 million. According to VISEN PHARMA's prospectus, the company's most...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02561"],"gpt_icon":0},{"id":"1171826434","title":"Innovative Drug Sector Maintains Strong Momentum, VISEN PHARMA-B (02561) Poised for \"Davis Double Play\"","url":"https://stock-news.laohu8.com/highlight/detail?id=1171826434","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1171826434?lang=en_us&edition=fundamental","pubTime":"2025-10-03 08:59","pubTimestamp":1759453188,"startTime":"0","endTime":"0","summary":"Since 2025, Hong Kong's pharmaceutical market has demonstrated structural outperformance, with the innovative drug sector becoming a focal point for capital allocation due to fundamental inflection...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","02561","159992","06978"],"gpt_icon":0},{"id":"1177779820","title":"Morgan Stanley: Enhanced Market Recognition of Biotech Stocks Drives Outperformance, Bullish on AKESO (09926) and Others","url":"https://stock-news.laohu8.com/highlight/detail?id=1177779820","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1177779820?lang=en_us&edition=fundamental","pubTime":"2025-09-23 10:04","pubTimestamp":1758593057,"startTime":"0","endTime":"0","summary":"Morgan Stanley released a research report stating that the total market capitalization of Chinese biotech stocks listed in Hong Kong has surged 154% year-to-date, significantly outpacing the Hang...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"079ddef7faa176ef1b029e2be2a3b56e","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1720050803.USD","LU0417516571.SGD","LU0348825331.USD","LU2488822045.USD","09926","09969","LU0561508036.HKD","HK0000252160.HKD","LU2328871848.SGD","LU2097828631.EUR","BK1589","LU0348827113.USD","LU0348735423.USD","09606","LU2097828557.USD","LU0348784397.USD","HK0000500386.USD","LU2242644610.SGD","BK1574","LU0634319403.HKD","LU2476274308.USD","02561","LU0417516902.SGD","IE00B543WZ88.USD","159837","LU2778985437.USD","LU2097828805.USD","BK1161","LU0540923850.HKD","LU0348783233.USD","IE00BPRC5H50.USD","LU2097828474.EUR","01801","02256","LU2476274720.SGD","LU0348767384.USD","LU2543165471.USD","LU0417516738.SGD","LU0502904849.HKD","LU1794554557.SGD","IE00B5MMRT66.SGD","LU0455707207.USD","LU0348766576.USD","BK1583","LU1969619763.USD","HK0000252152.HKD","LU2097828714.EUR"],"gpt_icon":0},{"id":"2563722853","title":"Visen Pharmaceuticals Expands Supply Agreement with Ascendis Group for Broader Product Access","url":"https://stock-news.laohu8.com/highlight/detail?id=2563722853","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563722853?lang=en_us&edition=fundamental","pubTime":"2025-08-31 20:17","pubTimestamp":1756642652,"startTime":"0","endTime":"0","summary":"Visen Pharmaceuticals has announced a supplemental agreement to its existing Commercial Supply Framework Agreement with Ascendis Europe. This amendment, signed on August 29, 2025, allows VISEN HK and its subsidiaries to purchase drug packages, auto-injectors, and ancillary products from Ascendis A/S and its subsidiaries. The modification aims to enhance flexibility and resource allocation within the Ascendis Group, benefiting both parties involved. The announcement follows a previous circular issued on June 12, 2025, regarding the connected transactions under the original framework. Executive Director and CEO of Visen Pharmaceuticals, Mr. LU An-Bang, emphasized that aside from the disclosed changes, all other details of the agreement remain unchanged.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and shoul","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250831:nNDL3VPCbm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02561"],"gpt_icon":0},{"id":"2562070730","title":"VISEN Pharmaceuticals' H1 Loss Widens 41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2562070730","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562070730?lang=en_us&edition=fundamental","pubTime":"2025-08-28 14:02","pubTimestamp":1756360959,"startTime":"0","endTime":"0","summary":"VISEN Pharmaceuticals  reported 118 million yuan in attributable loss for the first half of 2025, widening by 41% from a loss 83.5 million yuan a year earlier, according to a Hong Kong bourse filing Wednesday.Loss per share was 1.18 yuan, compared with 0.89 yuan in the prior year.It came as the company, which debuted on the Hong Kong bourse in March, continues to develop its core product called lonapegsomatropin, a long-acting growth hormone for the treatment of pediatric growth hormone deficiency.In July, the company partnered with Anhui Anke Biotechnology  to jointly promote the drug in specific regions of China.Shares of the pharmaceutical company fell 1.1% in midday trade Thursday.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0060","300009","BK1161","BK0042","BK0239","02561","BK0070"],"gpt_icon":0},{"id":"2562067740","title":"BRIEF-Visen Pharmaceuticals Logs HY Loss RMB118 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2562067740","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562067740?lang=en_us&edition=fundamental","pubTime":"2025-08-27 22:59","pubTimestamp":1756306755,"startTime":"0","endTime":"0","summary":"BRIEF-Visen Pharmaceuticals Logs HY Loss RMB118 MlnAug 27 (Reuters) - Visen Pharmaceuticals 2561.HK:HY LOSS RMB118 MILLIONFurther company coverage: 2561.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250827:nFWN3UJ0FQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02561","BK1161"],"gpt_icon":0},{"id":"2562174049","title":"Visen Pharmaceuticals Reports Increased Loss of RMB 118 Million for H1 2025; R&D and Administrative Expenses Rise Significantly","url":"https://stock-news.laohu8.com/highlight/detail?id=2562174049","media":"Reuters","labels":["executive","dataReport","event","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562174049?lang=en_us&edition=fundamental","pubTime":"2025-08-27 22:46","pubTimestamp":1756305998,"startTime":"0","endTime":"0","summary":"Visen Pharmaceuticals Reports Increased Loss of RMB 118 Million for H1 2025; R&D and Administrative Expenses Rise Significantly. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Visen Pharmaceuticals published the original content used to generate this news brief on August 27, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250827:nNDL9Cm74T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive,dataReport,event,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02561"],"gpt_icon":0},{"id":"1170723952","title":"VISEN PHARMA-B (02561) Reports Interim Results with R&D Costs of RMB 46.621 Million, Up 19.8% YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=1170723952","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1170723952?lang=en_us&edition=fundamental","pubTime":"2025-08-27 22:46","pubTimestamp":1756305981,"startTime":"0","endTime":"0","summary":"VISEN PHARMA-B (02561) announced its interim results for the six months ended June 30, 2025, recording other income of RMB 5.301 million during the period. Research and development costs reached RMB...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02561","BK1161"],"gpt_icon":0},{"id":"2562474035","title":"Visen Pharmaceuticals - Hy Loss RMB118 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2562474035","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562474035?lang=en_us&edition=fundamental","pubTime":"2025-08-27 22:35","pubTimestamp":1756305351,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250827:nFWN3UJ0FQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02561"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.visenpharma.com","stockEarnings":[{"period":"1week","weight":0.0195},{"period":"1month","weight":-0.057},{"period":"3month","weight":-0.1638},{"period":"6month","weight":-0.2784},{"period":"1year","weight":-0.4997},{"period":"ytd","weight":0.0494}],"compareEarnings":[{"period":"1week","weight":0.0296},{"period":"1month","weight":0.0669},{"period":"3month","weight":0.0664},{"period":"6month","weight":0.0845},{"period":"1year","weight":0.396},{"period":"ytd","weight":0.0505}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Visen Pharmaceuticals is a holding company mainly engaged in developing and commercializing disruptive endocrine therapies. The Company's main products under development include lonapegsomatropin, navepegritide, and palopegteriparatide. The lonapegsomatropin is used to treat growth hormone deficiency in children aged 3 to 17 years old. The navepegritide is a disease repair therapy used to treat children with cartilage dysplasia aged 2 to 10 years old. The palopegteriparatide is a treatment method used to treat adult hypoparathyroidism. The Company is in the late stage of research and development, and its products are close to commercialization.","exchange":"SEHK","name":"VISEN PHARMA-B","nameEN":"VISEN PHARMA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"VISEN PHARMA-B(02561),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest VISEN PHARMA-B(02561) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"VISEN PHARMA-B,02561,VISEN PHARMA-B股票,VISEN PHARMA-B股票老虎,VISEN PHARMA-B股票老虎国际,VISEN PHARMA-B行情,VISEN PHARMA-B股票行情,VISEN PHARMA-B股价,VISEN PHARMA-B股市,VISEN PHARMA-B股票价格,VISEN PHARMA-B股票交易,VISEN PHARMA-B股票购买,VISEN PHARMA-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"VISEN PHARMA-B(02561),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest VISEN PHARMA-B(02561) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}